Previous 10 | Next 10 |
Rocket Pharmaceuticals ( NASDAQ: RCKT ) said its gene therapy RP-A501 was safe, well tolerated and showed clinical benefit in two children and four adults in a phase 1 trial to treat Danon Disease (DD). DD is a rare genetic condition characterized by weakening ...
NEW YORK, NY / ACCESSWIRE / September 30, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Rocket Pharmaceuticals, Inc. (N...
— Pediatric efficacy data for both patients show initial improvements across clinical, functional and biomarker endpoints with six to nine months of follow-up; positive results including protein expression obtained at three and six months consistent with adult cohorts at simila...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer,...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock.com Renovacor (NYSEMKT: RCOR ) stock is gaining on Tuesday after announcing that Rocket Pharmaceuticals (NASDAQ: RCKT ) is acquiring it. That agreement will have Rocket Pharmaceutica...
Rocket Pharmaceuticals ( NASDAQ: RCKT ) is acquiring Renovacor ( NYSE: RCOR ) in an all-stock deal to bolster its position in AAV-based gene therapy for cardiac diseases. Under the agreement, Renovacor shareholders will receive ~0.1676 shares of Rocket in ex...
Acquisition further strengthens Rocket’s leadership in AAV-based cardiac gene therapy and expands Company’s near-term clinical assets for the treatment of heart conditions Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful comme...
— Updated Data from Phase 1 Danon Disease trial expected to include efficacy and safety data from pediatric cohort and longer-term data from adult cohort — — Company to webcast investor event on Sept. 30, at 8:00 a.m. ET — Rocket Pharmac...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer,...
Summary Shares have lost 15% year to date. Company wisely adopted a platform-agnostic approach to address first-in-class opportunities across the gene therapy pipeline. Danon disease presents their most lucrative opportunity, with conservative peak sales potential exceeding $2...
News, Short Squeeze, Breakout and More Instantly...
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a le...
2024-06-02 14:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...